Last updated: April 25, 2026
Which companies manufacture or supply naloxone hydrochloride?
Naloxone hydrochloride is supplied through two main routes: (1) finished-dose products (for acute opioid overdose response) and (2) active pharmaceutical ingredient (API) and intermediates used by branded and generic manufacturers.
What are the major finished-dose naloxone suppliers (US label / market presence)?
Below are widely distributed branded and generic naloxone products, which anchor the supply chain for end-use procurement.
| Product (naloxone form) |
Typical use |
Supplier / brand owner (examples) |
Notes for procurement |
| Narcan (naloxone hydrochloride, intranasal) |
Community and EMS |
Emergent BioSolutions |
One of the dominant US intranasal offerings. |
| Zimhi (naloxone hydrochloride, autoinjector) |
Community and first responders |
Sagent / Ritrat / supplier network varies by market |
Autoinjector format; procurement is typically through US distributors tied to label holders and contracted manufacturers. |
| Kloxxado (naloxone hydrochloride, intranasal) |
Community and EMS |
Eli Lilly (brand) |
Brand intranasal option with established distribution. |
| Generic naloxone hydrochloride injection (IM/IV) |
Clinical setting |
Multiple generic manufacturers |
Injection strengths and presentations vary by labeler; supply is fragmented and multi-sourced. |
Which API suppliers are commonly involved in naloxone hydrochloride supply?
API procurement is usually handled through qualified suppliers supplying either (a) naloxone hydrochloride API directly or (b) key synthetic intermediates under cGMP-to-client qualification frameworks. The naloxone API market is characterized by multiple qualified producers supplying generic injectables and finished intranasal products through contract manufacturing and contract manufacturing organizations (CMOs).
What categories of suppliers matter most for naloxone hydrochloride sourcing?
Supply risk and lead-time performance typically track these supplier categories:
- Finished-dose label holders and their manufacturing partners
- Intranasal and autoinjector products are commonly manufactured by a mix of internal manufacturing sites and outsourced CMO capacity under quality agreements.
- cGMP API manufacturers
- These supply naloxone hydrochloride for injection and for use in finished-dose manufacturing pipelines.
- Generic injectable manufacturers
- They often buy API and convert into finished injection under their own regulated quality systems and packaging lines.
- Distributors and authorized wholesalers
- Hospitals and government buyers frequently route through established distributor networks tied to cold-chain and handling requirements (where applicable by presentation).
What supplier selection criteria should buyers apply for naloxone hydrochloride?
Naloxone has a high-volume, time-critical clinical use profile. Supplier evaluation typically focuses on:
- cGMP compliance and inspection history (batch release controls)
- Change control maturity (especially for API synthesis route or particle/process parameters)
- Packaging and presentation availability (vial size, concentration, intranasal device compatibility)
- Supply continuity (multi-site manufacturing or dual sourcing)
- Regulatory coverage (US FDA ANDA/label compliance for finished products; DMF or equivalent documentation for API)
How do supplier roles differ for intranasal vs injection naloxone hydrochloride?
| Supply chain element |
Intranasal products |
Injection products |
| API to finished |
Naloxone hydrochloride API + formulation |
Naloxone hydrochloride API + parenteral formulation |
| Key manufacturing complexity |
Device-associated manufacturing and dose delivery performance |
Sterile fill-finish and container-closure integrity |
| Common bottlenecks |
Device component availability and validated formulation/device integration |
Sterile fill-finish capacity and batch release constraints |
What supply contracts and qualification structures are typical?
Procurement for naloxone hydrochloride usually follows one of these structures:
- Hospital and government procurement: through approved distributors with label-level assurance.
- Generic manufacturers: API qualification via DMF-linked documentation and stability/identity testing.
- Branded intranasal/autoinjector programs: through long-term QMS-controlled CMO/labeler agreements.
What practical supplier mapping should investors and R&D teams use?
For diligence or build/buy decisions, map supply chain nodes in this order:
- US brand label holder and their manufacturing network (finished dose)
- ANDA generic labelers supplying injection and intranasal equivalents (finished dose)
- API producers with documented regulatory filings and consistent release performance
- CMO capacity for sterile fill-finish (injection) or device/formulation integration (intranasal/autoinjector)
Key Takeaways
- Naloxone hydrochloride supply is anchored by finished-dose label holders for intranasal and autoinjector formats and by multi-source generic injection manufacturers for clinical use.
- API sourcing flows through cGMP API producers qualified by manufacturers under QMS and regulatory documentation frameworks.
- Supplier qualification for naloxone prioritizes cGMP compliance, validated manufacturing controls, packaging/device integration (for intranasal), and sterile fill-finish capacity (for injection).
FAQs
1) Who are the key US suppliers of naloxone hydrochloride intranasal products?
Emergent BioSolutions (Narcan), Eli Lilly (Kloxxado), and other intranasal label holders/generic equivalents operating through the US distribution network.
2) Who supplies naloxone hydrochloride autoinjectors in the US market?
Zimhi (naloxone hydrochloride autoinjector) is a primary branded option; the label-holder and manufacturing partner configuration is contract-driven through device-integrated manufacturing supply chains.
3) Is naloxone hydrochloride injection supplied by one manufacturer?
No. Injection supply is typically multi-manufacturer, with multiple generic labelers producing finished vials based on qualified API sourcing.
4) How should buyers qualify naloxone hydrochloride API suppliers?
They typically assess cGMP status, regulatory documentation (e.g., DMF where applicable), batch release controls, stability, and change control discipline tied to the client’s finished product specs.
5) What are the main causes of naloxone supply disruption?
Supply disruptions most commonly track sterile fill-finish capacity constraints for injection and device/formulation integration bottlenecks for intranasal/autoinjector products, compounded by limited qualified capacity at one or more supply-chain nodes.
References
[1] U.S. Food and Drug Administration (FDA). Drug approvals and labeling for naloxone-containing products (Narcan, Kloxxado, Zimhi). FDA Drug Databases. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. FDA. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] Centers for Disease Control and Prevention (CDC). Opioid overdose response guidance and use of naloxone. https://www.cdc.gov/overdose-prevention/
